title: Percutaneous comprehensive cryoablation for metastatic esophageal cancer after failure of radical surgery.
abstract: Esophageal cancer is common in China. There is a lack of treatment strategies for metastatic esophageal cancer (MEC) after radical surgery on the primary tumor. Cryoablation is an attractive option because tumor necrosis can be safely induced in a minimally invasive manner. This study assessed its therapeutic effect in MEC after failure of radical surgery. One hundred and forty patients met the inclusion criteria from May, 2003 to March, 2011. Comprehensive cryotherapy of multiple metastases was performed on 105 patients; 35 received chemotherapy. No severe complications occurred during or after cryoablation. Overall survival (OS) was assessed according to therapeutic protocol, pathologic type, treatment timing and number of procedures. The OS of patients who received comprehensive cryoablation (44 ± 20 months) was significantly longer than that of those who underwent chemotherapy (23 ± 24 months; P = 0.0006). In the cryotherapy group, the OS for squamous cell carcinoma (45 ± 19 months) was longer than that for adenocarcinoma (33 ± 18 months; P = 0.0435); the OS for timely cryoablation (46 ± 19 months) was longer than that for delayed cryoablation (33 ± 20 months; P = 0.0193); the OS for multiple cryoablation (50 ± 17 months) was longer than that for single cryoablation (37 ± 20 months; P = 0.0172); and the OS for cryo-immunotherapy (56 ± 17 months) was longer than that for cryoablation alone (39 ± 19 months; P = 0.0011). Thus, comprehensive cryotherapy may have advantages over chemotherapy in the treatment of MEC and, in patients with squamous cell carcinoma, supplementary immunotherapy and timely and multiple cryoablation may be associated with a better prognosis.
authors.forename: Xu
authors.initials: X
authors.lastname: Jiongyuan
authors.forename: Niu
authors.initials: N
authors.lastname: Lizhi
authors.forename: Mu
authors.initials: M
authors.lastname: Feng
authors.forename: Liu
authors.initials: L
authors.lastname: Shupeng
authors.forename: Leng
authors.initials: L
authors.lastname: Yin
authors.forename: Liao
authors.initials: L
authors.lastname: Mengtian
authors.forename: Zeng
authors.initials: Z
authors.lastname: Jianying
authors.forename: Yao
authors.initials: Y
authors.lastname: Fei
authors.forename: Chen
authors.initials: C
authors.lastname: Jibing
authors.forename: Li
authors.initials: L
authors.lastname: Jialiang
authors.forename: Xu
authors.initials: X
authors.lastname: Kecheng
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary* / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000556:secondary* / Q000601:surgery*; D003131:Combined Modality Therapy; D003452:Cryosurgery / Q000009:adverse effects / Q000379:methods*; D017679:Cryotherapy; D004938:Esophageal Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D004947:Esophagus / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009362:Neoplasm Metastasis / Q000628:therapy; D016896:Treatment Outcome